Compare BNR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNR | RFL |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 92.6M |
| IPO Year | 2019 | 2017 |
| Metric | BNR | RFL |
|---|---|---|
| Price | $9.40 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 236.8K |
| Earning Date | 06-05-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $111.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $5.31 | $1.12 |
| 52 Week High | $41.72 | $3.96 |
| Indicator | BNR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 49.67 |
| Support Level | $8.34 | $1.21 |
| Resistance Level | $10.00 | $3.96 |
| Average True Range (ATR) | 0.78 | 0.25 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 17.10 | 53.12 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.